<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10767">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627679</url>
  </required_header>
  <id_info>
    <org_study_id>MAP0010-CL-P101</org_study_id>
    <nct_id>NCT00627679</nct_id>
  </id_info>
  <brief_title>Safety and Blood Level Study of Unit Dose Budesonide</brief_title>
  <acronym>UDB P101</acronym>
  <official_title>A Randomized, Double Blind, Active Controlled, Single Dose, 4 Arm, 4 Period Crossover, Phase 1 Study Investigating the Tolerability and Pharmacokinetics of MAP0010</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Q-Pharm Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability and pharmacokinetics of three
      doses of MAP0010 (Unit Dose Budesonide) compared with Pulmicort Respules® (Budesonide) in
      healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010</measure>
    <time_frame>8 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010</measure>
    <time_frame>8 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax is the time to maximum concentration of a drug in the plasma. The Tmax of budesonide is reported in minutes (min).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-8) of Budesonide After Administration of Pulmicort Respules® and Three Doses of MAP0010</measure>
    <time_frame>8 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The AUC(0-8) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-8) is reported in picograms times minutes per milliliter (pg*min/ml).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010</measure>
    <time_frame>8 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The AUC(0-inf) is the area under the plot of plasma concentration of drug against time to infinity (inf) after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg*min/ml).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010</measure>
    <time_frame>8 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes (min).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment sequence: A, B, D, C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 4; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence: B, C, A, D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment visits were separated by a 48-72 hour washout period. Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 2; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 3; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 4; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence: C, D, B, A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment visits were separated by a 48-72 hour washout period. Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 2; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 3; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 4; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence: D, A, C, B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment visits were separated by a 48-72 hour washout period. Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 2; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 3; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 4; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide Inhalation Suspension</intervention_name>
    <description>Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.</description>
    <arm_group_label>Treatment sequence: A, B, D, C</arm_group_label>
    <arm_group_label>Treatment sequence: B, C, A, D</arm_group_label>
    <arm_group_label>Treatment sequence: C, D, B, A</arm_group_label>
    <arm_group_label>Treatment sequence: D, A, C, B</arm_group_label>
    <other_name>Pulmicort Respules®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAP0010 low dose</intervention_name>
    <description>Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.</description>
    <arm_group_label>Treatment sequence: A, B, D, C</arm_group_label>
    <arm_group_label>Treatment sequence: B, C, A, D</arm_group_label>
    <arm_group_label>Treatment sequence: C, D, B, A</arm_group_label>
    <arm_group_label>Treatment sequence: D, A, C, B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAP0010 intermediate dose</intervention_name>
    <description>Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.</description>
    <arm_group_label>Treatment sequence: A, B, D, C</arm_group_label>
    <arm_group_label>Treatment sequence: B, C, A, D</arm_group_label>
    <arm_group_label>Treatment sequence: C, D, B, A</arm_group_label>
    <arm_group_label>Treatment sequence: D, A, C, B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAP0010 high dose</intervention_name>
    <description>Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.</description>
    <arm_group_label>Treatment sequence: A, B, D, C</arm_group_label>
    <arm_group_label>Treatment sequence: B, C, A, D</arm_group_label>
    <arm_group_label>Treatment sequence: C, D, B, A</arm_group_label>
    <arm_group_label>Treatment sequence: D, A, C, B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult volunteers, aged 18-50 years

          -  BMI less than 30 kg/m2

          -  Non smoker (currently and &lt;10 pack years total if ex-smoker)

        Exclusion Criteria:

          -  Any use of corticosteroid in previous 4 weeks

          -  Pregnancy/lactation

          -  Significant blood donation (or testing) in previous 8 weeks
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Marjason, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Q-Pharm Pty Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q-Pharm Pty Limited</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>QLD 4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 9, 2013</lastchanged_date>
  <firstreceived_date>February 22, 2008</firstreceived_date>
  <firstreceived_results_date>August 19, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric asthma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All subjects received all 4 treatments in a randomly assigned order. The treatments were:
Treatment A: Pulmicort Respules® Treatment B: MAP0010 low dose Treatment C: MAP0010 intermediate dose Treatment D: MAP0010 high dose The sequences were Treatments ABDC, BACD, CDBA, DACB.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment A, B, D, C</title>
          <description>Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Pulmicort Respules® delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 4; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 5</description>
        </group>
        <group group_id="P2">
          <title>Treatment B, C, A, D</title>
          <description>Treatment visits were separated by a 48-72 hour washout period. Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 2; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 3; Treatment A = a single dose of Pulmicort Respules® delivered by nebulization at Visit 4; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 5</description>
        </group>
        <group group_id="P3">
          <title>Treatment C, D, B, A</title>
          <description>Treatment visits were separated by a 48-72 hour washout period. Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 2; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 3; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 4; Treatment A = a single dose of Pulmicort Respules® delivered by nebulization at Visit 5</description>
        </group>
        <group group_id="P4">
          <title>Treatment D, A, C, B</title>
          <description>Treatment visits were separated by a 48-72 hour washout period. Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 2; Treatment A = a single dose of Pulmicort Respules® delivered by nebulization at Visit 3; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 4; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 5</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>All patients that were enrolled in the study.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="23.3" spread="4.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010</title>
        <description>The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).</description>
        <time_frame>8 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients with available data at specified time points are included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>a single dose of Pulmicort Respules® delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>a single dose of MAP0010 low dose delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>a single dose of MAP0010 intermediate dose delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>a single dose of MAP0010 high dose delivered by nebulization as per protocol</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010</title>
            <description>The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).</description>
            <units>pg/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="303.5" spread="177.4"/>
                  <measurement group_id="O2" value="106.2" spread="63.47"/>
                  <measurement group_id="O3" value="239.9" spread="140.1"/>
                  <measurement group_id="O4" value="434.5" spread="246.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010</title>
        <description>Tmax is the time to maximum concentration of a drug in the plasma. The Tmax of budesonide is reported in minutes (min).</description>
        <time_frame>8 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients with available data at specified time points are included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>a single dose of Pulmicort Respules® delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>a single dose of MAP0010 low dose delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>a single dose of MAP0010 intermediate dose delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>a single dose of MAP0010 high dose delivered by nebulization as per protocol</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tmax of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010</title>
            <description>Tmax is the time to maximum concentration of a drug in the plasma. The Tmax of budesonide is reported in minutes (min).</description>
            <units>min</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9.063" spread="7.122"/>
                  <measurement group_id="O2" value="4.467" spread="3.270"/>
                  <measurement group_id="O3" value="3.125" spread="1.500"/>
                  <measurement group_id="O4" value="3.688" spread="1.448"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-8) of Budesonide After Administration of Pulmicort Respules® and Three Doses of MAP0010</title>
        <description>The AUC(0-8) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-8) is reported in picograms times minutes per milliliter (pg*min/ml).</description>
        <time_frame>8 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients with available data at specified time points are included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>a single dose of Pulmicort Respules® delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>a single dose of MAP0010 low dose delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>a single dose of MAP0010 intermediate dose delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>a single dose of MAP0010 high dose delivered by nebulization as per protocol</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC(0-8) of Budesonide After Administration of Pulmicort Respules® and Three Doses of MAP0010</title>
            <description>The AUC(0-8) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-8) is reported in picograms times minutes per milliliter (pg*min/ml).</description>
            <units>pg*min/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29040" spread="9316"/>
                  <measurement group_id="O2" value="3978" spread="1974"/>
                  <measurement group_id="O3" value="8626" spread="4184"/>
                  <measurement group_id="O4" value="22130" spread="9675"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-inf) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010</title>
        <description>The AUC(0-inf) is the area under the plot of plasma concentration of drug against time to infinity (inf) after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg*min/ml).</description>
        <time_frame>8 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients with available data at specified time points are included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>a single dose of Pulmicort Respules® delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>a single dose of MAP0010 low dose delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>a single dose of MAP0010 intermediate dose delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>a single dose of MAP0010 high dose delivered by nebulization as per protocol</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC(0-inf) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010</title>
            <description>The AUC(0-inf) is the area under the plot of plasma concentration of drug against time to infinity (inf) after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg*min/ml).</description>
            <units>pg*min/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31480" spread="10690"/>
                  <measurement group_id="O2" value="4391" spread="1423"/>
                  <measurement group_id="O3" value="7842" spread="3647"/>
                  <measurement group_id="O4" value="25290" spread="11750"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life (t1/2) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010</title>
        <description>Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes (min).</description>
        <time_frame>8 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>a single dose of Pulmicort Respules® delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>a single dose of MAP0010 low dose delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>a single dose of MAP0010 intermediate dose delivered by nebulization as per protocol</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>a single dose of MAP0010 high dose delivered by nebulization as per protocol</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Half-life (t1/2) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010</title>
            <description>Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes (min).</description>
            <units>min</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="145.4" spread="40.84"/>
                  <measurement group_id="O2" value="73.02" spread="33.43"/>
                  <measurement group_id="O3" value="78.35" spread="27.08"/>
                  <measurement group_id="O4" value="140.0" spread="54.19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>a single dose of Pulmicort Respules® delivered by nebulization as per protocol</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>a single dose of MAP0010 low dose delivered by nebulization as per protocol</description>
        </group>
        <group group_id="E3">
          <title>Treatment C</title>
          <description>a single dose of MAP0010 intermediate dose delivered by nebulization as per protocol</description>
        </group>
        <group group_id="E4">
          <title>Treatment D</title>
          <description>a single dose of MAP0010 high dose delivered by nebulization as per protocol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>vaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epitaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP, Scientific Affairs</name_or_title>
      <organization>MAP Pharmaceuticals Inc., a wholly owned subsidiary of Allergan</organization>
      <phone>(650) 386-3100</phone>
      <email>dkellerman@mappharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
